- Home
- LENZ vs BBNX Comparison
LENZ vs BBNX Comparison
Compare LENZ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- BBNX
- Stock Information
- Founded
- LENZ 2019
- BBNX 2015
- Country
- LENZ United States
- BBNX United States
- Employees
- LENZ N/A
- BBNX N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- BBNX Medical/Dental Instruments
- Sector
- LENZ Health Care
- BBNX Health Care
- Exchange
- LENZ Nasdaq
- BBNX Nasdaq
- Market Cap
- LENZ 1.2B
- BBNX 967.6M
- IPO Year
- LENZ 2021
- BBNX 2025
- Fundamental
- Price
- LENZ $39.70
- BBNX $21.42
- Analyst Decision
- LENZ Strong Buy
- BBNX Strong Buy
- Analyst Count
- LENZ 4
- BBNX 10
- Target Price
- LENZ $49.75
- BBNX $26.10
- AVG Volume (30 Days)
- LENZ 546.3K
- BBNX 1.0M
- Earning Date
- LENZ 11-05-2025
- BBNX 10-28-2025
- Dividend Yield
- LENZ N/A
- BBNX N/A
- EPS Growth
- LENZ N/A
- BBNX N/A
- EPS
- LENZ N/A
- BBNX N/A
- Revenue
- LENZ $5,000,000.00
- BBNX $78,022,000.00
- Revenue This Year
- LENZ N/A
- BBNX $43.04
- Revenue Next Year
- LENZ $285.82
- BBNX $35.60
- P/E Ratio
- LENZ N/A
- BBNX N/A
- Revenue Growth
- LENZ N/A
- BBNX 550.45
- 52 Week Low
- LENZ $16.54
- BBNX $8.89
- 52 Week High
- LENZ $50.40
- BBNX $26.66
- Technical
- Relative Strength Index (RSI)
- LENZ 42.78
- BBNX 50.82
- Support Level
- LENZ $45.20
- BBNX $21.57
- Resistance Level
- LENZ $49.25
- BBNX $23.41
- Average True Range (ATR)
- LENZ 2.80
- BBNX 1.33
- MACD
- LENZ -0.46
- BBNX -0.15
- Stochastic Oscillator
- LENZ 4.00
- BBNX 52.83
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.